A single 400-mg oral dose of sparfloxacin was given to each of six healthy male volunteers, and the concentrations of the drug were measured in plasma, cantharides-induced inflammatory fluid, and urine over the subsequent 52 h. The mean peak concentration in plasma of 1.6 tag/ml was attained at a mean time of 2.7 h postdose. The mean peak concentration in inflammatory fluid of 1.3 ,g/ml was attained at a mean time of 5 Antibiotic assays were performed within 1 h of sample collection by using a plate diffusion method; the test organism was Escherichia coli 4004 (Bayer AG, Wuppertal, Germany); the medium used was Iso-Sensitest agar (pH 7.2; Oxoid Ltd., Basingstoke, United Kingdom). Standards were prepared by using human serum (Bradshaw Biologicals, Leicester, United Kingdom) for serum samples, 70% human serum (to simulate the protein content of the inflammatory fluid) in pH 7 phosphate buffer for inflammatory fluid samples, and phosphate buffer at pH 7 for urine samples. Samples were applied by filling 5-mm-diameter wells cut into the plates, which were then incubated in air overnight at 30°C. The coefficient of variation within the assay was 9.4% at 0.75 ,ug/ml and 6.5% at 0.1 ,g/ml. The coefficients of variation between assays were 5.9 and 7.9%, respectively.
h postdose. The mean peak concentration in inflammatory fluid of 1.3 ,g/ml was attained at a mean time of 5 Sparfloxacin [AT-4140; 5-amino-l-cyclopropyl-6,8-difluoro-1,4-dihydro-7(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinolone-3-carboxylic acid] is a new difluorinated quinolone antimicrobial agent. In vitro studies have shown it to have greater activity than most other quinolones against grampositive species and only slightly less activity than ciprofloxacin against gram-negative species (1) . It also has good activity in vitro against many atypical pathogens, such as Chlamydia trachomatis (1), legionellae, mycobacteria, mycoplasmas (9) , and rickettsiae (11) .
The purpose of this study was to investigate the pharmacokinetics of sparfloxacin and its penetration into a chemically induced blister, which is similar in composition to a mild inflammatory exudate (14) , following a single oral dose. Antibiotic assays were performed within 1 h of sample collection by using a plate diffusion method; the test organism was Escherichia coli 4004 (Bayer AG, Wuppertal, Germany); the medium used was Iso-Sensitest agar (pH 7.2; Oxoid Ltd., Basingstoke, United Kingdom). Standards were prepared by using human serum (Bradshaw Biologicals, Leicester, United Kingdom) for serum samples, 70% human serum (to simulate the protein content of the inflammatory fluid) in pH 7 phosphate buffer for inflammatory fluid samples, and phosphate buffer at pH 7 for urine samples. Samples were applied by filling 5-mm-diameter wells cut into the plates, which were then incubated in air overnight at 30°C. The coefficient of variation within the assay was 9.4% at 0.75 ,ug/ml and 6.5% at 0.1 ,g/ml. The coefficients of variation between assays were 5.9 and 7.9%, respectively.
MATERIALS AND METHODS
The lower limit of sensitivity was 0.1 pg/ml. The standard range for the assay was 0.06 to 1 ,g/ml, and the assay was linear between these values.
Physical examinations and measurements of initial signs were repeated 3 and 7 days after the dose was administered.
Pharmacokinetic analysis of the plasma samples was performed by using the GPHARM program (4), assuming a two-compartment model using a weighted least-squares algorithm. Pharmacokinetic analysis of blister fluid samples was based on standard graphical methods (3, 5) . The area under the curve for time zero to infinity (AUCO,) was derived from the knowledge of the AUC for time zero to 52 h, the elimination constant, and the concentration at t = 52 h.
RESULTS
The mean concentrations in plasma and inflammatory fluid obtained are shown in Fig. 1 . The derived pharmacokinetic data are listed in Table 1 .
The rate of absorption of sparfloxacin was very variable, the time at which the maximum drug concentration (Tm..) in plasma was achieved ranging from 0. 
